Transforming the Trajectory: Early Inflammation Control as a Path to Lasting Change in Spondyloarthritis
Objectives:
Persistent inflammation in spondyloarthritis (SpA) drives long-term functional impairment and structural damage. This symposium will review how early intervention and effective therapy may influence disease progression, patient-reported outcomes and quality of life. Recent clinical trial data for bimekizumab will be discussed in the context of deep, rapid control of inflammation as well as sustained disease control and long-term management strategies.
| Agenda - Saturday 31 October | |
|---|---|
|
|
Chairperson: Prof Kichul Shin, Republic of Korea
|
|
1025 – 1030 |
Welcome and Introduction Prof Kichul Shin, Republic of Korea |
|
1030 – 1050 |
Timing Matters: Early Inflammation Control in SpA Prof Masato Okada, Japan |
|
1050 – 1110 |
Translating Trial Data into Practice: Bimekizumab in PsA and axSpA Prof Paul Bird, Australia |
|
1110 – 1120 |
Q&A and Discussion Prof Kichul Shin, Republic of Korea; Prof Masato Okada, Japan; Prof Paul Bird, Australia |
|
1120 – 1125 |
Close Prof Kichul Shin, Republic of Korea |
